Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy shows promise for hematologic malignancies but faces challenges with sustained remission.
• Identifying factors influencing CAR-T cell therapy efficacy is crucial for improving patient outcomes.

Purpose of the Study:

• To develop a predictive model for B-cell acute lymphoblastic leukemia (B-ALL) treatment efficacy using cellular adhesion genes.
• To investigate the role of integrin subunit beta 2 (ITGB2) in CAR-T cell therapy effectiveness.

Main Methods:

• Analysis of bone marrow sequencing data from B-ALL patients undergoing CD19 CAR-T cell therapy.
• Development and validation of a predictive model based on cellular adhesion genes.
• In vitro and in vivo experiments assessing the impact of ITGB2 inhibition/knockout and upregulation on CAR-T cell cytotoxicity.

Main Results:

• Cellular adhesion was identified as a key factor predicting clinical outcomes in CAR-T cell therapy.
• Inhibition or knockout of ITGB2 in malignant B cells reduced CAR-T cell efficacy against B-lineage tumors.
• Upregulation of ITGB2 enhanced CAR-T cell activity, linked to immunological synapse formation.

Conclusions:

• A novel predictive model for CD19 CAR-T cell therapy efficacy in B-ALL was developed based on cellular adhesion genes.
• The ITGB2 pathway plays a significant role in CAR-T cell-mediated eradication of B-cell malignancies.
• Targeting ITGB2 may offer therapeutic strategies to enhance CAR-T cell therapy outcomes.